comparemela.com
Latest Breaking News On - Phase 3 emerald 1 trial nct03778957 - Page 1 : comparemela.com
TACE Plus Durvalumab and Bevacizumab Could Alter SOC in Embolization-Eligible, Unresectable HCC
Riccardo Lencioni, MD, discusses how TACE, durvalumab, and bevacizumab, could represent a new standard of care in embolization-eligible HCC.
Italy
Riccardo-lencioni
Department-of-surgery
Cancers-symposium
Critical-area-pathology
Riccardo-lencioni
D
Chemoembolization-tace-
Urvalumab-imfinzi-
Nd-bevacizumab-avastin-
Hepatocellular-carcinoma
Hcc
vimarsana © 2020. All Rights Reserved.